Biocon Biologics Brand Guidelines: A 1978 Enzyme Firm, the Viatris Deal & a 2026 Return

An enzyme partner in Bengaluru.

Biocon Biologics is the biosimilars business of Biocon Limited, the Bengaluru company founded in 1978 by Kiran Mazumdar-Shaw. According to English Wikipedia, which cites a 2004 Forbes profile, Biocon began as Biocon India Private Limited, the Indian partner of Biocon Biochemicals, an Irish maker of enzymes for brewing. Its first products were enzymes such as papain, taken from papaya, and isinglass, the fish-derived agent used to clear some beers and wines.

The Irish link changed hands twice. In 1989 Unilever bought Biocon Biochemicals and merged it into its Quest International subsidiary; in 1998, Wikipedia says, Unilever sold its holding to Biocon’s Indian owners. Over the same years Biocon moved from enzymes toward medicines, and regulators in the United States and Europe began approving its products, starting, Wikipedia records, with the cholesterol drug lovastatin in 2001.

Wikipedia dates Biocon Biologics, the subsidiary for biologic medicines, to 2000. Biosimilars are follow-on versions of biologic medicines whose patents have expired, and Biocon Biologics says its own are developed at the Biocon Research Centre at Biocon Park in Bengaluru. The following decade set up its international role: Wikipedia records that in 2009 Biocon announced a strategic collaboration with the American generics maker Mylan to enter the global market for generic biologics, and that it opened a production site in Malaysia in 2010.

From partner to owner.

The Mylan partnership produced the products that made Biocon Biologics’ name abroad. Wikipedia records that the US Food and Drug Administration approved the Mylan–Biocon trastuzumab biosimilar, a version of the cancer drug Herceptin, in 2017, and that the European Commission approved their insulin glargine in 2018. Biocon Biologics says it was the first company to receive FDA approval for a biosimilar trastuzumab, in 2017, and for a biosimilar pegfilgrastim, in 2018, and that in July 2021 its insulin glargine, sold as Semglee, became the first biosimilar to receive an interchangeable designation from the FDA. It says that glargine is made at its plant in Malaysia.

In 2021 Biocon sold a 15 per cent stake in Biocon Biologics to the Serum Institute of India, the vaccine maker, in a deal that, Wikipedia says, also gave Biocon access to vaccine doses and commercial rights to Serum’s vaccines in international markets.

Then the partnership became a purchase. On 29 November 2022 Viatris, the company that by then held Mylan, announced that it had closed the sale of its biosimilars business to Biocon Biologics, taking a stake in Biocon Biologics as part of the payment. Under a transition services agreement, Viatris said, it would keep handling commercial and other services for about two years before Biocon Biologics took them over. Biocon Biologics calls the purchase “one of the biggest M&A deals in the Indian pharma space” and describes the result as a fully integrated biosimilars company.

Its portfolio page lists ten approved or commercial molecules across oncology, immunology, diabetes, eye health and bone health. Among the antibodies and proteins are biosimilars of trastuzumab, bevacizumab, adalimumab and aflibercept; among the insulins are recombinant human insulin and the analogues glargine and aspart. Denosumab and pertuzumab appear among its later-stage projects, and the company says its biosimilars are sold in more than 100 markets.

The category.

Biosimilar makers sell medicines that most people only ever meet as a pack in a pharmacy or a hospital ward, so their public image is built from the places where those medicines are made. Their websites and reports favour gleaming steel bioreactors, vials moving along blue-lit filling lines, scientists in gowns and hoods, and close-ups of prefilled syringes and autoinjector pens. The pictures signal scale and control rather than any single product.

The category is young. The European Medicines Agency’s record shows that the marketing authorisation for Celltrion’s Remsima, a biosimilar of the antibody infliximab, was issued on 10 September 2013, and English Wikipedia describes it as the first biosimilar monoclonal antibody approved by the EMA. Since then a group of companies in Asia, Europe and North America has built ranges of biosimilars, each sold under a brand name of its own, alongside the corporate names covered in this guide.

Their messaging leans on access. Celltrion states a mission of “a healthier tomorrow where no patients are left untreated”; Samsung Bioepis says it makes “quality-assured biologic medicines more accessible, more quickly.” Celltrion’s brand page ties its green to trust. Trade meetings such as the GRx+Biosims conference and the BIO International Convention are where the sector’s companies present their pipelines and meet partners.

This guide sets out what can be checked about each maker — who founded it, who owns it, and which approvals and deals dated sources record — and marks clearly what rests only on the company’s own word.

Back inside Biocon.

Biocon Biologics had been expected to list its own shares: in January 2025 its chief executive told Reuters it might do so by March 2026. Instead, on 6 December 2025, Biocon said it would make the unit a wholly owned subsidiary, buying out the minority holders — Serum Institute Life Sciences, Tata Capital Growth Fund II and Activ Pine — through a share swap and buying back the stake held by Viatris, Reuters reported in a story carried by Malaysia’s The Star. Biocon said it had weighed a public offering and a merger before choosing that route, and the integration was due by 31 March 2026.

On 27 March 2026 Contract Pharma reported that Shreehas Tambe, who had held the same titles at Biocon Biologics, would become chief executive and managing director of Biocon Limited from 1 April 2026, the first to do so “following the full integration of Biocon Biologics as its wholly owned subsidiary.” Kiran Mazumdar-Shaw is executive chairperson. The group now spans biosimilars, insulins, complex generics and peptides, and Biocon Biologics continues as a subsidiary inside it.

Where its medicines are made rests on the company’s own account. Biocon Biologics says its biosimilars come from three plants, two in Bengaluru and one in Johor, Malaysia; that it uses a yeast-based Pichia pastoris platform for insulins and mammalian cell lines for antibodies; and that its sites hold approvals from more than 25 regulators, including the FDA and the European Medicines Agency. It describes its antibody drug-substance building at Biocon Park as India’s first biopharmaceutical facility to win an award from the International Society for Pharmaceutical Engineering, and its Johor plant as a centre of excellence making insulin in vials, cartridges and delivery devices.

Its language centres on access: “patients first,” an “affordable innovation model,” and a stated vision “to be a global leader in biologics.” Those are its own words.

For a design guide, Biocon Biologics shows how a business can grow from a partner’s role into an owner’s, and then be folded back into its parent while keeping its own name. Compare Viatris, the partner whose biosimilars business it bought, and Sandoz, another company built around biosimilars and generics. For this guide we use a deep teal and a saffron with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Biocon Biologics’s identity on hand — save it to a board in the Made Good inspiration library.